|
Eisai Receives Confirmation that Aricept (donepezil hydrochloride), Orodispersible Tablet has Successfully Completed the Mutual Recognition Procedure in the 12 EU Countries
(Comtex Business)Tokyo, Japan, Dec 27, 2005 (JCN Newswire via COMTEX) --Eisai Co., Ltd. (TSE: 4523) announced that its U.K. subsidiary, Eisai Ltd., has received notification of the completion of the Mutual Recognition Procedure (MRP) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 22 (London time) for Aricept orodispersible tablet.
The MHRA confirmed that all 12 Member States involved in the procedure have mutually recognised the UK national licence approved by the MHRA earlier this year. The 12 Member States are Germany, France, Italy, Austria, Belgium, Denmark, Luxembourg, Finland, Greece, Ireland, Portuagal, and Sweden. All 12 Member States will now issue their own national licences in due course.
Aricept orodispersible tablet is designed to make administration easier for Alzheimer's disease patients who have difficulty swallowing tablets, in order to contribute to many patients by this new formualtion. The company has already started marketing an orodispersible tablet of Aricept in Japan since July 2004. In the U.S., Eisai started marketing orodispersible tablets from June 2005, and received approval in May 2005 in the UK.
Aricept, an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. Aricept is currently indicated for the treatment of mild to moderate Alzheimer's disease.
Eisai covers the major regions in Europe, and is making efforts to enhance its pharmaceutical sales structure in Europe. Through the new formulation approval of Aricept orodispersible tablet, Eisai will contribute to the medical benefits of patients in the EU through the enhancement of easier administration for Alzheimer's disease patient.
About Eisai Co., Ltd.
Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.
Contact:
Corporate Communications Department
Eisai Co., Ltd.
TEL: 81-3-3817-5120
[ Back To TMCnet.com's Homepage ]
|
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 16-18, 2008. Los Angeles, California.
